Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Amyloid-β associated cortical thinning in clinically normal elderly.

Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA.

Ann Neurol. 2011 Jun;69(6):1032-42. doi: 10.1002/ana.22333.

2.

Selective disruption of the cerebral neocortex in Alzheimer's disease.

Desikan RS, Sabuncu MR, Schmansky NJ, Reuter M, Cabral HJ, Hess CP, Weiner MW, Biffi A, Anderson CD, Rosand J, Salat DH, Kemper TL, Dale AM, Sperling RA, Fischl B; Alzheimer's Disease Neuroimaging Initiative..

PLoS One. 2010 Sep 23;5(9):e12853. doi: 10.1371/journal.pone.0012853.

3.

The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Caroli A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2010 Aug;31(8):1263-74. doi: 10.1016/j.neurobiolaging.2010.04.024.

4.

The clinical use of structural MRI in Alzheimer disease.

Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM.

Nat Rev Neurol. 2010 Feb;6(2):67-77. doi: 10.1038/nrneurol.2009.215. Review.

5.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

6.

Subregional neuroanatomical change as a biomarker for Alzheimer's disease.

Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM; Alzheimer's Disease Neuroimaging Initiative..

Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20954-9. Erratum in: Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6551. Fenema-Notestine, Christine [corrected to Fennema-Notestine, Christine].

7.

Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease.

Sluimer JD, van der Flier WM, Karas GB, van Schijndel R, Barnes J, Boyes RG, Cover KS, Olabarriaga SD, Fox NC, Scheltens P, Vrenken H, Barkhof F.

Eur Radiol. 2009 Dec;19(12):2826-33. doi: 10.1007/s00330-009-1512-5.

8.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative..

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

9.

MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.

Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

Brain. 2009 Apr;132(Pt 4):1067-77. doi: 10.1093/brain/awp007.

10.

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Brain. 2009 May;132(Pt 5):1310-23. doi: 10.1093/brain/awn320.

11.

The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals.

Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL.

Cereb Cortex. 2009 Mar;19(3):497-510. doi: 10.1093/cercor/bhn113.

12.

Neurodevelopmental trajectories of the human cerebral cortex.

Shaw P, Kabani NJ, Lerch JP, Eckstrand K, Lenroot R, Gogtay N, Greenstein D, Clasen L, Evans A, Rapoport JL, Giedd JN, Wise SP.

J Neurosci. 2008 Apr 2;28(14):3586-94. doi: 10.1523/JNEUROSCI.5309-07.2008.

13.

Atrophy rates accelerate in amnestic mild cognitive impairment.

Jack CR Jr, Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, Gunter JL, Knopman DS, Boeve BF, Smith GE, Petersen RC.

Neurology. 2008 May 6;70(19 Pt 2):1740-52.

14.

Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults.

Marcus DS, Wang TH, Parker J, Csernansky JG, Morris JC, Buckner RL.

J Cogn Neurosci. 2007 Sep;19(9):1498-507.

PMID:
17714011
15.

3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.

Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr.

Brain. 2007 Jul;130(Pt 7):1777-86.

16.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9.

PMID:
17210801
17.

Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.

Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC.

Lancet Neurol. 2006 Oct;5(10):828-34.

PMID:
16987729
18.

Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.

Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC.

Neurology. 2005 Oct 25;65(8):1227-31.

19.

Cortical thinning in cingulate and occipital cortices in first episode schizophrenia.

Narr KL, Toga AW, Szeszko P, Thompson PM, Woods RP, Robinson D, Sevy S, Wang Y, Schrock K, Bilder RM.

Biol Psychiatry. 2005 Jul 1;58(1):32-40.

PMID:
15992520
20.

The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study.

Amieva H, Jacqmin-Gadda H, Orgogozo JM, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF.

Brain. 2005 May;128(Pt 5):1093-101.

Items per page

Supplemental Content

Support Center